Valerio Therapeutics to Absorb Valour Bio Unit to Streamline Legal Structure

11:57 PM EST, 11/02/2025 (MT Newswires) -- Valerio Therapeutics (ALVIO.PA) agreed to absorb its 90.01%-owned subsidiary Valour Bio to streamline its legal structure, according to an Oct. 31 release. Under the deal, Valour Bio's minority shareholders will receive shares in the holding company in exchange for their shareholding in the subsidiary. Valour Bio will be dissolved upon completion of the merger. Shareholders of the French biotechnology company will consider the transaction during an extraordinary general meeting expected to be held in early December. The retroactive date of effectivity for the transaction was Jan. 1.